Maria Laura Saiz, Laura Lozano-Chamizo, Aida Bernardo Florez, Marzia Marciello, Paula Diaz-Bulnes, Viviana Corte-Iglesias, Cristian Ruiz Bernet, Raul R Rodrigues-Diez, Cristina Martin-Martin, Mar Rodriguez-Santamaria, Ivan Fernandez-Vega, Ramon M Rodriguez, Carmen Diaz-Corte, Beatriz Suarez-Alvarez, Marco Filice, Carlos Lopez-Larrea
Targeting epigenetic mechanisms has emerged as a potential therapeutic approach for the treatment of kidney diseases. Specifically, inhibiting the bromodomain and extra-terminal (BET) domain proteins using the small molecule inhibitor JQ1 has shown promise in preclinical models of acute kidney injury (AKI) and chronic kidney disease (CKD). However, its clinical translation faces challenges due to issues with poor pharmacokinetics and side effects. Here, we developed engineered liposomes loaded with JQ1 with the aim of enhancing kidney drug delivery and reducing the required minimum effective dose by leveraging cargo protection...
March 26, 2024: Biomedicine & Pharmacotherapy